CD40配體(CD40L)單克隆抗體
Monoclonal Antibody to Cluster Of Differentiation 40 Ligand (CD40L)
CD154; TRAP; HIGM1; IGM; IMD3; TBAM; T-BAM; TNFSF5; Gp39; TNF Superfamily Member 5; Hyper-IgM Syndrome; TNF-Related Activation Protein; T-Cell B-Cell Activating Molecule
- 編號(hào)UMAA119Hu23
- 物種Homo sapiens (Human，人) 相同的名稱，不同的物種。
- 來(lái)源單抗制備
- 宿主小鼠
- 效價(jià)(克隆號(hào))C6
- Ig亞型 IgG1 Kappa
- 純化方式蛋白A + 蛋白G親和純化
- 標(biāo)記物無(wú)標(biāo)記物
- 免疫原 RPA119Hu02-CD40配體(CD40L)重組蛋白
- 緩沖液成份0.01M 磷酸鹽緩沖液（pH7.4，containing 0.05% Proclin-300，50% glycerol）
- 性狀液體
- 濃度1mg/mL
- 且適物種Rattus norvegicus (Rat，大鼠)
- 應(yīng)用WB
如果抗體需用于流式細(xì)胞術(shù)，請(qǐng)參見(jiàn)流式抗體。 - 下載 英文說(shuō)明書 中文說(shuō)明書
- 規(guī)格 20μl100μl 200μl 1ml 10ml
- 價(jià)格 ¥ 312 ¥ 729 ¥ 1041 ¥ 2603 ¥ 10410
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
Western Blot; Sample: Lane1: Rat Spleen lysate; Lane2: Hela cell lysate Primary Ab: 3μg/ml Mouse Anti-Human CD40L Antibody Second Ab: 0.2μg/mL HRP-Linked Caprine Anti-Mouse IgG Polyclonal Antibody (Catalog: SAA544Mu19)
-
通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
該抗體是針對(duì)CD40L的小鼠單克隆抗體。在免疫組織化學(xué)染色和免疫印跡實(shí)驗(yàn)中能識(shí)別CD40L。
用法
Western blotting: 0.5-2μg/mL;
Immunohistochemistry: 5-20μg/mL;
Immunocytochemistry: 5-20μg/mL;
Optimal working dilutions must be determined by end user.
儲(chǔ)存
經(jīng)常使用則4°C保存。-20°C保存不超過(guò)兩年。避免反復(fù)凍融。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定，具體方法如下：在37°C孵育48小時(shí)，沒(méi)有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當(dāng)?shù)臈l件下存儲(chǔ)，損失率低于5%。
贈(zèng)品
增值服務(wù)
抗體標(biāo)記定制服務(wù)
Protein-A/G純化柱
細(xì)胞和組織染色液
抗體陽(yáng)性對(duì)照品
組織/切片定制服務(wù)
磷酸化抗體定制服務(wù)
免疫印跡(WB)實(shí)驗(yàn)服務(wù)
免疫組織化學(xué)(IHC)實(shí)驗(yàn)服務(wù)
免疫細(xì)胞化學(xué)(ICC)實(shí)驗(yàn)服務(wù)
流式細(xì)胞術(shù)(FCM)實(shí)驗(yàn)服務(wù)
免疫沉淀(IP)實(shí)驗(yàn)服務(wù)
免疫熒光(IF)實(shí)驗(yàn)服務(wù)
緩沖液
DAB顯色試劑盒
SABC試劑盒
長(zhǎng)臂生物素標(biāo)記試劑盒
實(shí)時(shí)熒光定量PCR實(shí)驗(yàn)服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| URPA119Hu02 | CD40配體(CD40L)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| URPA119Hu04 | CD40配體(CD40L)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| URPA119Hu01 | CD40配體(CD40L)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| URPA119Hu03 | CD40配體(CD40L)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UPAA119Hu02 | CD40配體(CD40L)多克隆抗體 | WB |
| UPAA119Hu03 | CD40配體(CD40L)多克隆抗體 | IHC; ICC/IF |
| UPAA119Hu01 | CD40配體(CD40L)多克隆抗體 | WB; IHC; ICC; IP. |
| ULAA119Hu71 | CD40配體(CD40L)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| ULAA119Hu81 | CD40配體(CD40L)多克隆抗體(異硫氰酸熒光素標(biāo)記) | WB; IHC; ICC; IF. |
| UMAA119Hu21 | CD40配體(CD40L)單克隆抗體 | IHC |
| UMAA119Hu23 | CD40配體(CD40L)單克隆抗體 | WB |
| UMAA119Hu22 | CD40配體(CD40L)單克隆抗體 | IHC; ICC/IF |
| UMAA119Hu25 | CD40配體(CD40L)單克隆抗體 | IHC |
| UMAA119Hu24 | CD40配體(CD40L)單克隆抗體 | IHC; ICC/IF |
| URAA119Hu21 | CD40配體(CD40L)重組抗體 | WB; IF; ICC; IHC; IP; FCM. |
| URAA119Hu22 | CD40配體(CD40L)重組抗體 | WB; IF; ICC; IHC; IP; FCM. |
| USEA119Hu | CD40配體(CD40L)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| ULMA119Hu | CD40配體(CD40L)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Basic Research in Cardiology | Secretome of apoptotic peripheral blood cells (APOSEC) attenuates microvascular obstruction in a porcine closed chest reperfused acute myocardial infarction model: role of platelet aggregation and vasodilation [PubMed: 22899170] |
| Molecules | The Protective Effects of Alisol A 24-Acetate from Alisma canaliculatum on Ovariectomy Induced Bone Loss in Vivo [Pubmed:26760992] |
| Journal of Neuroinflammation | Th17-skewed immune response and cluster of differentiation 40 ligand expression in canine steroid-responsive meningitis-arteritis, a large animal model for neutrophilic meningitis. [pubmed:28114998] |
| BMC Nephrology | Renal effects of metallothionein induction by zinc in vitro and in vivo [pubmed:28302075] |
| Toxicology and Applied Pharmacology | Effects of diisononyl phthalate on osteopenia in intact mice [pubmed:28893586] |
| INTERNATIONAL JOURNAL OF CARDIOLOGY | Short and long-term changes in platelet and inflammatory biomarkers after cryoballoon and radiofrequency ablation [Pubmed: 30857843] |
| Available at SSRN 3335365? | Evaluating the Platelet Activation Related to the Degradation of Biomaterials by Scheme of Molecular Markers [] |
| Data in Brief | Data for short and long-term prothrombotic biomarkers after cryoballoon and radiofrequency ablation [] |
| journal of thoracic and cardiovascular surgery | Evaluating Platelet Activation Related to the Degradation of Biomaterials Using Molecular Markers [Pubmed: 32812629] |
| Thrombosis Research | Feasibility study of use of rabbit blood to evaluate platelet activation by medical devices [Pubmed: 31838449] |
| Cancers | Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study [Pubmed: 32085544] |
| Persistently higher serum sCD40L levels are associated with mortality in septic patients [] | |
| Journal of Orthopaedic Translation | Tyloxapol inhibits RANKL-stimulated osteoclastogenesis and ovariectomized-induced bone loss by restraining NF-|êB and MAPK activation [33981577] |
| Bioactive Materials | Secretions from hypochlorous acid-treated tumor cells delivered in a melittin hydrogel potentiate cancer immunotherapy [34820587] |
